SAGE Therapeutics Inc. (SAGE)

164.06
5.20 3.30
NASDAQ : Health Technology
Prev Close 158.84
Open 160.19
Day Low/High 159.65 / 163.03
52 Wk Low/High 79.88 / 188.82
Volume 127.04K
Avg Volume 648.50K
Exchange NASDAQ
Shares Outstanding 50.72M
Market Cap 7.95B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know

FedEx, Federal Reserve, Google, AMD, Sage Therapeutics - 5 Things You Must Know

U.S. stock futures turn lower as investors await a key decision on interest rates from the Federal Reserve; FedEx sinks after issuing its second warning about fiscal 2019 profit; Google's new cloud-based video-game playing and sharing platform, Stadia, will be powered by chips made by Advanced Micro Devices.

Sage Therapeutics Announces FDA Approval Of ZULRESSO™ (brexanolone) Injection, The First And Only Treatment Specifically Indicated For Postpartum Depression

Sage Therapeutics Announces FDA Approval Of ZULRESSO™ (brexanolone) Injection, The First And Only Treatment Specifically Indicated For Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

Sage Therapeutics Surges on FDA Approval of Postpartum Depression Drug

First treatment for common childbirth complication wins FDA OK.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces Closing Of $575 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics Announces Closing Of $575 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of...

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its...

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500,000,000 of...

Sage Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 19, 2019

Sage Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 19, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board Of Directors

Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board Of Directors

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.

Notable Tuesday Option Activity: SAGE, RESI, EAT

Notable Tuesday Option Activity: SAGE, RESI, EAT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 4,304 contracts has been traded thus far today, a contract volume which is representative of approximately 430,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.5% of SAGE's average daily trading volume over the past month, of 852,990 shares.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

Stock doubles in value on positive Stage 3 trial results showing "meaningful" treatment of postpartum depression symptoms.

Sage Therapeutics To Provide Update On Key 2019 Initiatives At J.P. Morgan Healthcare Conference

Sage Therapeutics To Provide Update On Key 2019 Initiatives At J.P. Morgan Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer, Jeff Jonas, M.

Sage Therapeutics Announces SAGE-217 Meets Primary And Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression

Sage Therapeutics Announces SAGE-217 Meets Primary And Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 8, 2019

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 8, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Piper Jaffray 30th Annual Healthcare Conference

Sage Therapeutics To Present At Piper Jaffray 30th Annual Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30 th Annual...

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Notable Tuesday Option Activity: SAGE, REN, TSLA

Notable Tuesday Option Activity: SAGE, REN, TSLA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 4,861 contracts have traded so far, representing approximately 486,100 underlying shares. That amounts to about 101.3% of SAGE's average daily trading volume over the past month of 479,955 shares.

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference...

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the third quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company's common stock.

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Let's see what the charts and indicators look like.